Relacorilant
Corcept Therapeutics (CORT)
Decision dateDec 17, 2026
32 days away
Marketer take
A resubmission decision for the same molecule already approved as Lifyorli in ovarian cancer, so watch for distinct branding and for whether endocrinology messaging on hypercortisolism screening expands with it.
- Sponsor company
- Corcept Therapeutics (CORT)
- Indication
- Cushing's syndrome (resubmitted NDA)
- Therapeutic area
- Endocrinology
- Event
- PDUFA target action date
- Date
- Dec 17, 2026
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?